Wechselwirkungen · Descovy
Descovy 200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 11–12
HOS-134973 · Präparat HOS-097638
11 Medicinal product by Effects on medicinal product levels. Recommendation concerning therapeutic areas1 Mean percent change in AUC, co-administration with Descovy Cmax, Cmin2 ANTIDEPRESSANTS Sertraline (50 mg once daily), Tenofovir alafenamide: No dose adjustment of sertraline is tenofovir alafenamide (10 mg AUC: ↔ required. Dose Descovy according once daily)3 Cmax: ↔ to the concomitant antiretroviral (see section 4.2). Sertraline: AUC: ↑ 9% Cmax: ↑ 14% HERBAL PRODUCTS St. John’s wort (Hypericum Interaction not studied with either of Co-administration of Descovy with perforatum) the components of Descovy. St. John’s wort is not recommended. Co-administration of St. John’s wort, a P-gp inducer, may decrease tenofovir alafenamide plasma concentrations, which may result in loss of therapeutic effect and development of resistance. IMMUNOSUPPRESSANTS Ciclosporin Interaction not studied with either of The recommended dose of Descovy the components of Descovy. is 200/10 mg once daily.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sertraline (HOS-086247)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage d485db78a24090b415c8bf4419de249f79bf7209cb756b5e1ea61c20432afd54 · Zeichen 19163–21072 im Abschnitt